RBC Capital Markets increased its price target for Aurinia Pharmaceuticals from $16 to $18.

Nov 2, 2026, 9:42 AM ETOpinionRead the original at marketscreener.com

Neutral

RBC raised its target, but kept its Sector Perform rating and noted speculative risk. The higher target alone does not clearly change Aurinia's outlook.

AUPH · Aurinia Pharmaceuticals Inc.

AI read · Neutral

The AI's read

A price target is RBC's estimate, not a change to Aurinia's business. The unchanged rating and warning of speculative risk make the higher estimate less decisive. The story gives no new company results, so it does not clearly change how Aurinia's prospects look.

Get alerts for AUPH

Follow Aurinia Pharmaceuticals Inc. (AUPH) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AUPH

Free on the App Store and Google Play, or on the web.